恶性肿瘤放化疗致乙型肝炎病毒再激活防治进展

摘要/Abstract

摘要：乙型肝炎病毒感染者接受放化疗时可能出现病毒再激活，引起急性肝功能损伤。预防性抗病毒治疗可以减少病毒再激活及其相关病的发生，但尚缺乏统一的应用规范，因此需要多学科合作并开展更多前瞻性研究，以明确抗病毒治疗的个体化方案。

汪孟森, 于甬华. 恶性肿瘤放化疗致乙型肝炎病毒再激活防治进展[J]. 国际肿瘤学杂志, 2014, 41(3): 184-187.

WANG Meng-Sen, YU Yong-Hua. Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation[J]. Journal of International Oncology, 2014, 41(3): 184-187.

［1］ Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination［J］. Vaccine, 2009, 27(47):65506557. ［2］ Chen WQ. Estimation of cancer incidence and mortality in China 20042005［J］. Chin J Oncol, 2009, 31(9):664668. ［3］ Wands J, Chura CM, Roll FJ, et al. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders［J］. Gastroenterology, 1975, 68(1):105112. ［4］ Yeo W, Chan PK, Zhong S, et al. Frequency of Hepatitis B Virus reactivation in cancer patients undergoing cykotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors［J］. J Med Viorl, 2000, 62(3):299307. ［5］ Kawsar HI, Shahnewaz J, Gopalakrishna KV, et al. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis［J］. Clin Adv Hematol Oncol, 2012, 10(6):370378. ［6］ Post A, Nagendra S. Reactivation of hepatitis B: pathogenesis and clinical implications［J］. Curr Infect Dis Rep, 2009, 11(2):113119. ［7］ Jang JW, Kwon JH, You CR, et al. Risk of HBV reactmation according to viral status and treatment intensity in patients with hepatocellular carcinoma［J］. Antivir Ther, 2011, 16(7):969977. ［8］ Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours［J］. Br J Cancer, 2013, 108(10):19311935. ［9］ Niitsu N, Hagiwara Y, Tanae K, et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large Bcell lymphoma after rituximab combination chemotherapy［J］. J Clin Oncol, 2010, 28(34):50975100. ［10］ Yeo W, Chan TC, Leung NW, et al.Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab［J］.J Clin Oncol, 2009, 27, 605611. ［11］ Sema Sezgin G, Bilal S, Coskun HS. Hepatitis B reactivation related to everolimus ［J］. World J Hepatol, 2013, 5(1):4345. ［12］ Fujimoto Y, Hashimoto N, Kinoshita M, et al. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis［J］. Int J Clin Oncol, 2012, 17(3):290293. ［13］ Ohno M, Narita Y, Miyakita Y, et al.Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide—case report［J］. Neurol Med Chir (Tokyo), 2011, 51(10):728731. ［14］ Kim IK, Kim BG, Kim W, et al. Clinical prediction of failure of Lamivudine prophylaxis for hepatitis B virusinfected patients undergoing cytotoxic chemotherapy for malignancy［J］. Antimicrob Agents Chemother， 2012, 56(11):55115519. ［15］ Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version)［J］. Zhonghua Liu Xing Bing Xue Za Zhi， 2011, 32(4):405415. ［16］ European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection［J］. J Hepatol, 2012, 57(1):167185. ［17］ Wong V, Chan H. Chronic hepatitis B: a treatment update［J］. Semin Liver Dis, 2013, 33(2):122129. ［18］ Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in postoperative breast cancer patients receiving anthracycline based adjuvant chemotherapy［J］. Br J Cancer, 2011, 104(4):559563. ［19］ Chen XQ, Peng JW, Lin GN,et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAgpositive patients with diffuse large Bcell lymphoma undergoing prolonged rituximab therapy［J］. Med Oncol, 2012, 29(2):12371241. ［20］ Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after threedimensional conformal radiotherapy in patients with hepatitis B virusrelated hepatocellular［J］. Int J Radiat Oncol Biol Phys, 2007, 69(3):813819. ［21］ Marcellin P, Chang TT, Lim SG, et al. Longterm efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigenpostitive chronic hepatitis B［J］. Hepatology, 2008, 48(3):750758. ［22］ Chen FW, Coyle L, Jones BE, et al. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease［J］. Liver Int, 2013, 33(8):12031210. ［23］ Kim SJ, Hsu C, Song YQ, et al. Hepatitis B virus reactivation in Bcell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group［J］. Eur J Cancer, 2013, 49(16):34863496. ［24］ Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acuteonchronic liver failure［J］. Hepatology, 2011, 53(3):774780. ［25］ Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases［J］. J Clin Oncol, 2010, 28(19):31993202.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

恶性肿瘤放化疗致乙型肝炎病毒再激活防治进展

Progress of prevention and cure of chemoradiotherapy-related hepatitis B virus reactivation

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价